AstraZeneca has announced that the FDA has approved Tagrisso for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.

Www.pharmatimes.com/intcr

Freenome has announced that it has raised $254m from new and existing investors, intended to be used for the advancement of its single-cancer and tailored multi-cancer early detection tests developed on its multiomics platform.

Samedan ltd presents International Clinical Trials (ICT)

Welcome to the March 2024 issue of Pharmafocus!

Considering the increase in measles cases and the benefits of vaccination

Pharmarole.com

GSK has announced that the FDA has granted fast track designation for bepirovirsen, an investigational antisense oligonucleotide for the treatment of chronic hepatitis b.

Johnson & Johnson has announced that the FDA has granted breakthrough therapy designation for nipocalimab for the treatment of alloimmunised pregnant individuals at high risk of severe haemolytic disease of the foetus and newborn.

Argenx has announced that the FDA has accepted a supplemental biologics license application (sBLA) for Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for priority review.

Domainex has announced that it has opened a new biology centre of excellence at the Unity Campus at Pampisford, Cambridge, UK, in order to further support collaborations with pharmaceutical and biotechnology companies, patient foundations and academic institutions.

Roche has announced data from stage 1 of the NIH-sponsored phase 3 outmatch trial, which assessed the safety and efficacy of Xolair (omalizumab) in patients allergic to peanuts and at least two other common foods.

Boehringer Ingelheim has announced results from the phase 2 trial of Survodutide for the treatment of liver disease due to metabolic dysfunction-associated steatohepatitis (MASH).

ViiV Healthcare has announced results from an interim analysis of the phase 3 LATITUDE trial, which assessed Cabenuva (cabotegravirandrilpivirine), a long-acting injectable antiretroviral treatment (ART) for HIV treatment.

Tenax Therapeutics has announced that it has enrolled the first patient in its phase 3 level study, which aims to assess TNX-103 (oral levosimendan) for the treatment of pulmonary hypertension in heart failure with preserved ejection fraction.

Www.flypharmaeurope.com

Pfizer has announced that the EC has granted marketing authorisation for Velsipity (etrasimod) in the EU.

Ipsen has announced that the FDA has approved the supplemental new drug application for Onivyde (irinotecan liposome injection) plus oxaliplatin, fluorouracil and ;eucovorin (Nalirifox) as a first-line treatment for adult patients with metastatic pancreatic adenocarcinoma (mpdac).

Www.pharmafile.com

AbbVie has announced that the NICE has recommended Tepkinly (epcoritamab) as a treatment option for adults with diffuse large b-cell lymphoma (DLBCL) whose cancer has returned or not responded to two previous treatments.

Vertex Pharmaceuticals has announced that the European Commission (EC) has granted conditional marketing authorisation to Casgevy (exagamglogene autotemcel), a crispr/cas9 gene-edited therapy.

Communique.awardsplatform.com

AbbVie and Tentarix Biotherapeutics have announced that they have entered a multi-year collaboration focused on the discovery and development of conditionally active, multi-specific biologic candidates in oncology and immunology.

Astellas Pharma and Kelonia Therapeutics have announced that Xyphos Biosciences (a wholly owned subsidiary of Astellas) and Kelonia have entered into a research collaboration and licence agreement for the development of novel immuno-oncology therapeutics.

Www.samedanltd.com

BioNTech and Autolus Therapeutics have announced that they have entered a strategic collaboration intended to further both companies’ autologous CAR T programmes towards commercialisation following regulatory authorisations.

Vivet Therapeutics has announced that it has received €4.9m financing from the French Government for the advanced development of a gene therapy for the treatment of cerebrotendinous xanthomatosis (CTX), a rare neurodegenerative disease.

Novartis has announced that it has entered an agreement to acquire Morphosys AG for €2.7bn, or €68 per share.

Zuellig Pharma has announced that it has completed the acquisition of two brands, Cialis (tadalafil) and Alita (pemetrexed), from Eli Lilly for selected ASEAN markets, including Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines and Thailand.

Jazz Pharmaceuticals and Redx Pharma have announced that the companies have signed a definitive agreement under which Jazz will acquire Redx’s kirsten rat sarcoma virus (KRAS) inhibitor programme.

Www.pharmatimes.com/croy

Professor Tobias Arkenau from Ellipses Pharma explores the need and potential for next generation treatments as well as the global need to keep improving the clinical trial structure and landscape

Dr Gen Li, president at Phesi, considers patient enrolment and retention in clinical trials, with a focus on oncology trials and the challenges facing them

Pharmafocus speaks to Gilead Sciences about the current treatments available for blood cancers and how they are likely to develop in the future

Santosh Sahu at Charac considers the NHS’ Pharmacy First scheme, it benefits and the barriers to its implementation

Emma Bishop at Cognitant Group explores the need for patient support programmes, and how these can be improved

Betsy Goodfellow from Pharmafocus considers the current rise of measles cases in the UK and the measures that should be taken to prevent further infections

Www.samedanltd.com

Amylyx Pharmaceuticals has announced that it has appointed Andrew Caldwell to general manager UK and Ireland.

French biotech company StromaCare has announced the appointment of Georges Rawadi as chief executive officer (CEO).

Cuttsy+Cuttsy has announced the appointment of Jon Hume as commercial director, taking his new role from 1 March 2024.

AdhereTech has announced that it has appointed Paul Sekhri to its board of directors, having begun his new role on 7 February 2024.

Five key facts about measles

Get in touch @Pharmafocus on x.com

Www.pharmafile.com